NO20064676L - Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre - Google Patents

Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre

Info

Publication number
NO20064676L
NO20064676L NO20064676A NO20064676A NO20064676L NO 20064676 L NO20064676 L NO 20064676L NO 20064676 A NO20064676 A NO 20064676A NO 20064676 A NO20064676 A NO 20064676A NO 20064676 L NO20064676 L NO 20064676L
Authority
NO
Norway
Prior art keywords
dimethylsuccinyl
betulinic acid
dsb
pharmaceutical salts
salts
Prior art date
Application number
NO20064676A
Other languages
English (en)
Inventor
Martin Dale Power
David Eugene Martin
Original Assignee
Panacos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacos Pharmaceuticals Inc filed Critical Panacos Pharmaceuticals Inc
Publication of NO20064676L publication Critical patent/NO20064676L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives salter av 3-O-(3',3'-dimetylsuccinyl) betulinsyre (DSB). Spesielt beskrives fremstilling, farmasøytisk evaluering og in vivo biotilgjengelighetsevaluering av N-metyl-D-glucamin og alkaliesaltformer av DSB. Videre beskrives farmasøytiske preparater inkludert disse saltformer for anvendelse i metoder for behandling av HIV og relaterte sykdommer. Det tilveiebringes også metoder for å fremstille saltene av DSB og også de farmasøytiske preparater.
NO20064676A 2004-03-17 2006-10-16 Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre NO20064676L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55355404P 2004-03-17 2004-03-17
US58467404P 2004-07-02 2004-07-02
PCT/US2005/008935 WO2005090380A1 (en) 2004-03-17 2005-03-17 Pharmaceuticals salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid

Publications (1)

Publication Number Publication Date
NO20064676L true NO20064676L (no) 2006-12-01

Family

ID=34993638

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064676A NO20064676L (no) 2004-03-17 2006-10-16 Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre

Country Status (11)

Country Link
US (2) US20050239748A1 (no)
EP (1) EP1730163A4 (no)
JP (1) JP2007529544A (no)
AU (1) AU2005224260A1 (no)
BR (1) BRPI0508854A (no)
CA (1) CA2560266A1 (no)
IL (1) IL178128A0 (no)
MX (1) MXPA06010592A (no)
NO (1) NO20064676L (no)
RU (1) RU2387665C2 (no)
WO (1) WO2005090380A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610668A2 (pt) 2005-04-12 2010-07-13 Panacos Pharmaceuticals Inc polimorfas de di-n-metil-d-glucamina do ácido 3-o-(3',3'-dimetilsuccinil) betulìnico
CN101374527A (zh) * 2005-12-16 2009-02-25 帕纳克斯医药公司 3-o-(3’,3’-二甲基琥珀酰基)桦木酸的药物盐的制备方法
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CZ300722B6 (cs) * 2006-09-27 2009-07-22 Univerzita Karlova v Praze, Prírodovedecká fakulta Zpusob prípravy inkluzního komplexu pentacyklických a tetracyklických terpenoidu a farmaceutického prostredku obsahujícího tento inkluzní komplex, inkluzní komplex pentacyklického nebo tetracyklického terpenoidu a farmaceutický prostredek obsahující
US9505800B2 (en) 2006-11-03 2016-11-29 Myrexis, Inc. Extended triterpene derivatives
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
JP2009120516A (ja) * 2007-11-13 2009-06-04 Tokyo Medical Univ 抗ウィルス剤
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802727B2 (en) * 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
JP5752789B2 (ja) * 2010-06-04 2015-07-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害剤としての修飾ｃ−３ベツリン酸誘導体
WO2012095705A1 (en) * 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
RS54352B1 (en) 2011-01-31 2016-02-29 Bristol-Myers Squibb Company C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV INVESTIGATION INHIBITORS
SG192144A1 (en) 2011-01-31 2013-08-30 Bristol Myers Squibb Co C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
RU2489147C2 (ru) * 2011-08-31 2013-08-10 Людмила Петровна Лазурина Фармацевтическая антибактериальная композиция для местного применения на основе активных биометаллокомплексов
WO2013043778A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
SG11201505639SA (en) 2013-02-06 2015-08-28 Bristol Myers Squibb Co C-19 modified triterpenoids with hiv maturation inhibitory activity
KR20150121712A (ko) 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
CR20160472A (es) 2014-04-11 2017-03-10 Viiv Healthcare Uk (No 4) Ltd Triterpenoides con actividad inhibidora de la maduración del vih
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
AU2015346311A1 (en) 2014-11-14 2017-06-08 Viiv Healthcare UK (No5) Limited C17-aryl substituted betulinic acid analogs
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN107638571B (zh) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞口服药物组合物及其制备方法
CN107625967B (zh) 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 一种特考韦瑞注射用药物组合物及其制备方法
KR102295179B1 (ko) 2017-09-14 2021-08-30 피닉스 바이오테크놀러지 인코포레이티드. 바이러스 감염 치료를 위한 방법 및 조성물
AU2018334467B2 (en) 2017-09-14 2022-10-20 Phoenix Biotechnology, Inc. Method and improved neuroprotective composition for treating neurological conditions
AU2019292599B2 (en) 2018-06-29 2022-03-03 Dfh Therapeutics Triterpene amine derivatives
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
MX2020009095A (es) 2020-03-31 2022-07-28 Phoenix Biotechnology Inc Metodo y composiciones para el tratamiento de infeccion por coronavirus.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839344A (en) * 1973-03-28 1974-10-01 Schering Corp N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid
US4205073A (en) * 1975-04-30 1980-05-27 Schering Corporation Anti-diarrheal anilino nicotinic acids and method of using same
US4377583A (en) * 1981-08-21 1983-03-22 Mead Johnson & Company N-Methyl-D-glucamine salt of with 3,4-dihydro-5-methyl-6-(2-methylpropyl)-4-oxothieno[2,3-d]pyrimidine-2-carboxylic acid
JPS60163897A (ja) * 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd ウルソデオキシコ−ル酸メグルミン塩およびその注射剤
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
ZA927923B (en) * 1991-10-16 1993-04-26 Schering Corp Lipophilic oligosaccharide antibiotic salt compositions.
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
GB9613455D0 (en) * 1996-06-27 1996-08-28 Aston Molecules Ltd Analogues or derivatives of quercetin
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
WO1999045025A1 (en) * 1998-03-02 1999-09-10 The University Of North Carolina At Chapel Hill Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
JP2002518521A (ja) * 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
US7365221B2 (en) * 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
EP1594435A4 (en) * 2003-01-29 2006-12-27 Panacos Pharmaceuticals Inc INHIBITION OF HIV-1 REPLICATION BY TREATMENT OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
WO2005030790A1 (en) * 2003-09-26 2005-04-07 Panacos Pharmaceuticals, Inc. Novel triterpene derivatives, preparation thereof and use thereof

Also Published As

Publication number Publication date
JP2007529544A (ja) 2007-10-25
RU2006136409A (ru) 2008-04-27
RU2387665C2 (ru) 2010-04-27
EP1730163A1 (en) 2006-12-13
AU2005224260A1 (en) 2005-09-29
US20120214775A1 (en) 2012-08-23
BRPI0508854A (pt) 2007-08-28
EP1730163A4 (en) 2009-12-30
US20050239748A1 (en) 2005-10-27
IL178128A0 (en) 2006-12-31
WO2005090380A1 (en) 2005-09-29
CA2560266A1 (en) 2005-09-29
MXPA06010592A (es) 2007-06-12

Similar Documents

Publication Publication Date Title
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
TNSN07290A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
NO20021701L (no) Fremgangsmåte for fremstilling av et konjugat av polyglutamat og et terapeutisk middel
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
NZ709704A (en) Protein formulations and methods of making same
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
PL1687305T3 (pl) Pochodne 1H-imidazochinolin jako inhibitory kinaz białkowych
BRPI0916356A2 (no)
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
NO20063277L (no) Farmasoytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmate og anvendelse derav
TW200745155A (en) Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
NO20075758L (no) Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
TW200800977A (en) A new salt
WO2008074960A3 (fr) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
YU19302A (sh) 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application